Pyxis Oncology (PYXS) Receivables - Net (2024 - 2025)

Pyxis Oncology (PYXS) posted quarterly Receivables - Net of $3.0 million for Q2 2025, down 62.5% quarter-over-quarter from $8.0 million in Q1 2024.

Pyxis Oncology (PYXS) Receivables - Net (2024 - 2025) Analysis & Trends

Pyxis Oncology (PYXS) has reported Receivables - Net for 2 consecutive years, with $3.0 million the latest figure, recorded in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Pyxis Oncology	199.01 Mn	166.02 Mn	-

Download Data